These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 12845688

  • 1. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A.
    Int J Cancer; 2003 Sep 01; 106(3):455-7. PubMed ID: 12845688
    [Abstract] [Full Text] [Related]

  • 2. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos G, Palermos J, Yataganas X, Goldman JM, Rahemtulla A.
    Eur J Haematol; 2003 Jan 01; 70(1):34-42. PubMed ID: 12631257
    [Abstract] [Full Text] [Related]

  • 3. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D.
    Br J Haematol; 2003 Nov 01; 123(4):730-7. PubMed ID: 14616979
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C, Liu Y, Qin H, Li X, Guo W, Li J, Wang W, Qu L, Hu H, Xu C, Zheng L, Huang Y, Liu B, Gao H, Halleen JM, Liu X.
    Clin Chim Acta; 2013 Nov 15; 426():102-7. PubMed ID: 24055775
    [Abstract] [Full Text] [Related]

  • 5. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK.
    Acta Oncol; 2005 Nov 15; 44(7):742-7. PubMed ID: 16227166
    [Abstract] [Full Text] [Related]

  • 6. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Miyoshi Y.
    Breast Cancer; 2017 Mar 15; 24(2):245-253. PubMed ID: 27040403
    [Abstract] [Full Text] [Related]

  • 7. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
    Mose S, Menzel C, Kurth AA, Obert K, Breidert I, Borowsky K, Böttcher HD.
    Anticancer Res; 2003 Mar 15; 23(3C):2783-8. PubMed ID: 12926113
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.
    Br J Haematol; 2006 Dec 15; 135(5):688-92. PubMed ID: 17107351
    [Abstract] [Full Text] [Related]

  • 9. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E.
    Anticancer Res; 2006 Dec 15; 26(4B):3127-32. PubMed ID: 16886645
    [Abstract] [Full Text] [Related]

  • 10. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ.
    Osteoporos Int; 2005 Sep 15; 16(9):1109-16. PubMed ID: 15605190
    [Abstract] [Full Text] [Related]

  • 11. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
    Chao TY, Wu YY, Janckila AJ.
    Clin Chim Acta; 2010 Nov 11; 411(21-22):1553-64. PubMed ID: 20599857
    [Abstract] [Full Text] [Related]

  • 12. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
    Terpos E, Palermos J, Viniou N, Vaiopoulos G, Meletis J, Yataganas X.
    Calcif Tissue Int; 2001 May 11; 68(5):285-90. PubMed ID: 11683535
    [Abstract] [Full Text] [Related]

  • 13. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep 11; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
    Chen CJ, Chao TY, Janckila AJ, Cheng SN, Ku CH, Chu DM.
    J Pediatr Endocrinol Metab; 2005 Jan 11; 18(1):55-62. PubMed ID: 15679069
    [Abstract] [Full Text] [Related]

  • 15. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J, Izumi N, Kasahara H, Tagawa H, Chiba T, Nihei H.
    Nihon Jinzo Gakkai Shi; 2010 Jan 11; 52(8):1022-8. PubMed ID: 21254698
    [Abstract] [Full Text] [Related]

  • 16. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
    Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J, Yataganas X.
    Eur J Haematol; 2000 Nov 11; 65(5):331-6. PubMed ID: 11092464
    [Abstract] [Full Text] [Related]

  • 17. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC, Ku CH, Chao TY, Yu JC, Chen MM, Lee SH.
    Cancer Epidemiol Biomarkers Prev; 2006 Mar 11; 15(3):424-8. PubMed ID: 16537696
    [Abstract] [Full Text] [Related]

  • 18. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
    Rissanen JP, Suominen MI, Peng Z, Halleen JM.
    Calcif Tissue Int; 2008 Feb 11; 82(2):108-15. PubMed ID: 18084692
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
    Mose S, Menzel C, Kurth AA, Obert K, Ramm U, Eberlein K, Boettcher HD, Pichlmeier U.
    Anticancer Res; 2005 Feb 11; 25(6C):4639-45. PubMed ID: 16334155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.